Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02478502
Other study ID # 2012/1627 b
Secondary ID 2012-004418-32
Status Terminated
Phase Phase 2
First received
Last updated
Start date June 2015
Est. completion date December 31, 2022

Study information

Verified date February 2024
Source University Hospital, Akershus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Germ cell tumors belong to the most chemosensitive malignancies. Paclitaxel in combination with ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ cell cancer. Cabazitaxel may overcome resistance to docetaxel and paclitaxel and might have clinical activity in patients with metastatic and progressive germ cell tumors.


Description:

Patients with metastatic germ cell cancer and relapse after two or more courses of cisplatin-based chemotherapy or after high-dose chemotherapy have a poor prognosis and no curative options. Taxanes in various combinations unfold cytotoxic effects on germ cell tumors resistant to conventional doses of cisplatin. Paclitaxel in combination with ifosfamide and cisplatin (TIP) has become a common regimen for salvage treatment of germ cell cancer. In most patients, however, resistance to paclitaxel, as evidenced by progression occurs.Cabazitaxel has been developed to overcome resistance to docetaxel and paclitaxel. It has shown efficacy in patients progressing during docetaxel therapy in a large phase III trial (TROPIC) in patients with castration-resistant prostate cancer. Furthermore, chemotherapy resistance might be less likely to develop in patients receiving cabazitaxel as compared to other taxanes.


Recruitment information / eligibility

Status Terminated
Enrollment 14
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male patients = 18 years old - Histologically verified metastatic germ cell cancer (GCC) of the testicle or extragonadal GCC originating from retroperitoneum or mediastinum - Disease progression during cisplatin-based chemotherapy or Disease progression or relapse after high-dose chemotherapy or Disease progression or relapse after at least 2 different cisplatin-based regimens - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-2 - Life expectancy = 3 months - At baseline adequate function of liver, kidneys and bone marrow: ·Neutrophils = 1.5 x 109/L· - Hemoglobin = 9.0 g/dL - Platelets = 100 x 109/L - Creatinine = 1.5 x upper limit of normal (ULN) - Total Bilirubin = 1.0 x ULN - Serum glutamate oxaloacetate transaminase (SGOT/AST) = 1.5 x ULN - Serum glutamate pyruvate transaminase (SGPT/ALT) < 1.5 x ULN Exclusion Criteria: - Systemic antitumor treatment within 21 days before study entry - Simultaneous radiotherapy to the only target lesion - Patients unwilling or unable to comply with the protocol - Patients with unstable angina pectoris, myocardial infarction = 6 months prior to first study treatment, congestive heart failure New York Heart Association (NYHA) III-IV or serious uncontrolled cardiac arrhythmias - Patients with an active or uncontrolled infection - Patients who have a history of another primary malignancy and are off treatment for = 3 years, with the exception of non-melanoma skin cancer - Patients who have undergone major surgery within 4 weeks prior to starting study drug (e.g. intra-thoracic, intra-abdominal, or intra-pelvic) or significant traumatic injury, or who have not recovered from the side effects of any of the above within 6 weeks - Patients who have participated in another interventional clinical trial within 30 days before study entry - Other serious medical conditions that could impair the ability of the patient to participate in the study - Active infection requiring systemic antibiotic-, anti-viral-, or anti-fungal medication - Neuropathy =Grade 2 Common Terminology Criteria for Adverse Events (CTCAE) - Patient with reproductive potential not implementing accepted and effective method of contraception during the whole study period and up to 6 months after the last dose of cabazitaxel - One or more of the following cabazitaxel-specific requirements: - History of severe hypersensitivity reaction (= Grade 3) to docetaxel - History of severe hypersensitivity reaction (= Grade 3) to polysorbate 80 containing drugs - Concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome P450 3A4 (CYP3A4) (a one week wash-out period is necessary for patients who are already on these treatments) (see Appendix A and B) - Concurrent or planned treatment with Organic anion transporting polypeptide1B1 (OATP1B1) substrates e.g. statins, valsartan, repaglinide which have to be taken within 12 hours before cabazitaxel application and 3 hours after the end of infusion, refer table 9

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
cabazitaxel
cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy

Locations

Country Name City State
Denmark Rigshospitalet Copenhagen
Italy Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T) Meldola
Norway Oslo University Hospital Oslo
Sweden University Hospital of Uppsala, Department of Oncology Uppsala

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Akershus Sanofi

Countries where clinical trial is conducted

Denmark,  Italy,  Norway,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate Recist 1.1 after 3 and 6 cycles of cabazitaxel (9 and 18 weeks, respectively) as change from baseline (radiologic evaluation before first cycle of cabazitaxel)
See also
  Status Clinical Trial Phase
Recruiting NCT00772694 - Sorafenib Monotherapy in Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy Phase 2
Completed NCT00705094 - Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients N/A
Terminated NCT00531687 - Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer Phase 2
Completed NCT00216801 - Relationship of Ochratoxin A to Upper Urologic Cancers N/A
Terminated NCT00820287 - Identification of Predictive Markers for Testis Cancer in a Population of Men With High Risk N/A
Active, not recruiting NCT03142802 - Low-Dose CT - Stage I Testicular Cancer N/A
Recruiting NCT03232541 - The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting N/A
Completed NCT03557177 - Clinical Characterisation of the Vascular Effects of Cis-platinum Based Chemotherapy in Patients With Testicular Cancer
Active, not recruiting NCT01783145 - Shared Care Follow-up After Chemotherapy for Testicular Cancer
Recruiting NCT05611307 - Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Completed NCT02573584 - Vascular Fingerprint Validation Study
Recruiting NCT05670938 - Follow-up After Surgery for Testicular Cancer
Recruiting NCT02994758 - Development of Diagnostics and Treatment of Urological Cancers N/A
Completed NCT02991209 - Study of Testosterone vs Placebo in Testicular Cancer Survivors Phase 2/Phase 3
Completed NCT02602041 - Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners; A Pilot Study
Completed NCT02092740 - REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg N/A
Completed NCT01482741 - Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging N/A
Active, not recruiting NCT01242072 - Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies Phase 1
Completed NCT01242631 - Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer Phase 2
Completed NCT01135849 - B-Receptor Signaling in Cardiomyopathy N/A